Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Sandra Kreitz | Researchclopedia

Back to researchers

Sandra Kreitz

Bristol-Myers Squibb (Switzerland)

17

Works

216

Citations

3

h-index

2

i10-index

Research Topics

Acute Myeloid Leukemia Research Myeloproliferative Neoplasms: Diagnosis and Treatment Hemoglobinopathies and Related Disorders

Affiliations

Bristol-Myers Squibb (United States)2023–2023

Bristol-Myers Squibb (Switzerland)2023–2024

Top Works

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Uwe Platzbecker,Matteo Giovanni Della Porta,et al.

2023159 citations

Neutropenia and Cancer Infections

Multiple Myeloma Research and Treatments

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Matteo Della Porta,Guillermo Garcia‐Manero,et al.

202446 citations

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Guillermo Garcia‐Manero,Uwe Platzbecker,et al.

20233 citations

Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study

Esther Natalie Olíva,Uwe Platzbecker,et al.

20242 citations

Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).

Guillermo Garcia‐Manero,Uwe Platzbecker,et al.

20232 citations

Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.

Amer M. Zeidan,Uwe Platzbecker,et al.

20242 citations

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Esther Natalie Olíva,Uwe Platzbecker,et al.

20231 citations

Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS)

Guillermo Garcia‐Manero,Matteo Giovanni Della Porta,et al.

20241 citations

MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

Guillermo Garcia‐Manero,Uwe Platzbecker,et al.

20230 citations